Real-World Outcomes of First-Line Palbociclib Plus Endocrine Therapy for HR+/HER2− Metastatic Breast Cancer in Japan: A Single-Center Retrospective Study
In routine Japanese practice, palbociclib plus ET provided prolonged PFS and high disease control consistent with pivotal trials and international real-world evidence. Importantly, elderly patients tolerated treatment well, and selected PS 2-3 patients also derived clinical benefit. These findings indicate that neither age nor PS alone should preclude the use of palbociclib in carefully monitored real-world patients.
Authors
- Keiko Yanagihara (ORCID: https://orcid.org/0000-0003-2708-4550)
- Sayuri Kato (ORCID: https://orcid.org/0009-0005-2014-2385)
- Koji Nagata (ORCID: https://orcid.org/0000-0002-4704-0603)
- Miki Tamura (ORCID: https://orcid.org/0000-0003-0763-1174)
- Kentaro Awaji (ORCID: https://orcid.org/0000-0003-3864-5587)
- Takashi Yamakawa (ORCID: https://orcid.org/0000-0002-9528-9198)
- Masato Yoshida
Institutions
- Nippon Medical School (JP)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-12-04
- DOI
- https://doi.org/10.32604/or.2025.073891
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00